Sandbox: wdx causes: Difference between revisions
Jump to navigation
Jump to search
Line 11: | Line 11: | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ||
! colspan=" | ! colspan="11" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! colspan=" | ! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings | ||
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
Line 19: | Line 19: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History | ||
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ||
| colspan=" | | colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ||
|- | |- | ||
! colspan=" | ! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
|- | |- | ||
! rowspan="2" |Physiologic | ! rowspan="2" |Physiologic | ||
Line 28: | Line 28: | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal pain | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Asplenia | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hepatosplenomegaly | ||
! | |||
! | |||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ||
Line 37: | Line 39: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! rowspan="2" |BUN/Cr | |||
! rowspan="2" |LFT | |||
|- | |- | ||
!autonomous | !autonomous | ||
!reactive | !reactive | ||
!Lymphadenopathy | |||
!Joint redness | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | ||
|- | |- | ||
! rowspan=" | ! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic | ||
! align="center" style="background:#DCDCDC;" |Hereditary neutrophilia | ! align="center" style="background:#DCDCDC;" |Hereditary neutrophilia | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 61: | Line 67: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 68: | Line 76: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" | | ! align="center" style="background:#DCDCDC;" |'''Hereditary chronic neutrophilia''' | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 87: | Line 97: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 94: | Line 106: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" | | ! align="center" style="background:#DCDCDC;" |'''Myeloproliferative neoplasms''' | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 113: | Line 127: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 120: | Line 136: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 139: | Line 157: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 146: | Line 166: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" | | ! align="center" style="background:#DCDCDC;" |'''Microangiopathic hemolytic anemia (MAHA)''' | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 165: | Line 187: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 172: | Line 196: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |||
!'''Leukoerythroblastosis''' | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |Immature thrombocytopenia | ! align="center" style="background:#DCDCDC;" |Immature thrombocytopenia | ||
Line 191: | Line 247: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 198: | Line 256: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan=" | ! rowspan="12" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunology/ | ||
Rheumatology | Rheumatology | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition | ||
Line 219: | Line 279: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice | ||
! | |||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | ||
Line 226: | Line 288: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! | |||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|- | |||
!'''Leukocyte adhesion deficiency''' | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!'''Cryopyrin-associated periodic syndromes''' | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |Rheumatoid arthritis | ! align="center" style="background:#DCDCDC;" |Rheumatoid arthritis | ||
Line 245: | Line 369: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 252: | Line 378: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 271: | Line 399: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 278: | Line 408: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!adult Still's disease | !adult Still's disease | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 308: | Line 444: | ||
|- | |- | ||
!Kawasaki disease | !Kawasaki disease | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 349: | Line 489: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 356: | Line 498: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |||
!Sarcoidosis | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |Chronic hepatitis | ! align="center" style="background:#DCDCDC;" |Chronic hepatitis | ||
Line 375: | Line 549: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 382: | Line 558: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Sweet syndrome | !Sweet syndrome | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 427: | Line 609: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 434: | Line 618: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 454: | Line 640: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 461: | Line 649: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 480: | Line 670: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 487: | Line 679: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 499: | Line 693: | ||
! | ! | ||
!Children | !Children | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 517: | Line 715: | ||
|- | |- | ||
!granulomatous infections | !granulomatous infections | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 543: | Line 745: | ||
|- | |- | ||
!bronchiectasis | !bronchiectasis | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 568: | Line 774: | ||
! | ! | ||
|- | |- | ||
! rowspan=" | ! rowspan="5" |Metabolic | ||
!Diabetic coma | !Diabetic coma | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 596: | Line 806: | ||
|- | |- | ||
!Acidosis | !Acidosis | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 622: | Line 836: | ||
|- | |- | ||
!Thyroid strom | !Thyroid strom | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 647: | Line 865: | ||
! | ! | ||
|- | |- | ||
! | !Hypercortisolism | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 673: | Line 895: | ||
! | ! | ||
|- | |- | ||
!Seizures | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 717: | Line 942: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice | ||
! | |||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | ||
Line 724: | Line 951: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! | |||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|- | |- | ||
! rowspan=" | ! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications | ||
! align="center" style="background:#DCDCDC;" |Steriod | ! align="center" style="background:#DCDCDC;" |Steriod | ||
| align="center" style="background:#F5F5F5;" + |Release of granulocytes from the bone marrow | | align="center" style="background:#F5F5F5;" + |Release of granulocytes from the bone marrow | ||
Line 744: | Line 973: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 751: | Line 982: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |||
!myeloid growth factors | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |Lithium | ! align="center" style="background:#DCDCDC;" |Lithium | ||
Line 770: | Line 1,033: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 777: | Line 1,042: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 796: | Line 1,063: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 803: | Line 1,072: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 822: | Line 1,093: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 829: | Line 1,102: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Catecholamines (epinephrine) | !Catecholamines (epinephrine) | ||
|Stimulation of bone marrow myelopoiesis and/or egress into the circulation | |Stimulation of bone marrow myelopoiesis and/or egress into the circulation | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!ATRA | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
! | |||
!Allergy | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 876: | Line 1,215: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 883: | Line 1,224: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 902: | Line 1,245: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 909: | Line 1,254: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Cigarette smoking | !Cigarette smoking | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 938: | Line 1,289: | ||
! | ! | ||
|- | |- | ||
!Stress | !'''Stress/Exercise''' | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 980: | Line 1,335: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 987: | Line 1,344: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,006: | Line 1,365: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,013: | Line 1,374: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,019: | Line 1,382: | ||
!Platelet clumping | !Platelet clumping | ||
!Spurious | !Spurious | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 1,046: | Line 1,413: | ||
!Mixed cryoglobulinemia | !Mixed cryoglobulinemia | ||
!Spurious | !Spurious | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 1,087: | Line 1,458: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice | ||
! | |||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | ||
Line 1,094: | Line 1,467: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! | |||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|} | |} | ||
<references /> | <references /> |
Revision as of 18:38, 13 September 2018
Differentiating Leukocytosis from Other Diseases
- Leukocytosis is defined as an elevated white blood cell (WBC) count greater than 11,000 per mm3 (11.0 × 109 per L).
- The most common type of leukocytosis is neutrophilia.
- Neutrophilia can be defined as an increase in the absolute number of mature neutrophils to greater than 7,000 per mm3 [7.0 × 109 per L].
Category | Condition | Etiology | Mechanism | Congenital | Acquried | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Signs | ||||||||||||||||||||||||||
Lab Findings | |||||||||||||||||||||||||||||
Physiologic | increased bone marrow production | demargination of peripheral blood neutrophils | Appearance | Fever | Abdominal pain | BP | Asplenia | Hepatosplenomegaly | Other | CBC | PBS | Bone marrow exam | ESR/CRP | BUN/Cr | LFT | ||||||||||||||
autonomous | reactive | Lymphadenopathy | Joint redness | WBC | HB | Plt | |||||||||||||||||||||||
Hematologic | Hereditary neutrophilia | ||||||||||||||||||||||||||||
Hereditary chronic neutrophilia | |||||||||||||||||||||||||||||
Myeloproliferative neoplasms | |||||||||||||||||||||||||||||
Polycythemia Vera | |||||||||||||||||||||||||||||
Microangiopathic hemolytic anemia (MAHA) | |||||||||||||||||||||||||||||
Leukoerythroblastosis | |||||||||||||||||||||||||||||
Immature thrombocytopenia | |||||||||||||||||||||||||||||
Immunology/
Rheumatology |
Condition | Etiology | Physiologic | Congenital | Acquried | Demography | History | Appearance | Fever | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | ESR/CRP | Gold standard | Associated findings | |||||||
Leukocyte adhesion deficiency | |||||||||||||||||||||||||||||
Cryopyrin-associated periodic syndromes | |||||||||||||||||||||||||||||
Rheumatoid arthritis | |||||||||||||||||||||||||||||
Juvenile onset rheumatoid arthritis | |||||||||||||||||||||||||||||
adult Still's disease | |||||||||||||||||||||||||||||
Kawasaki disease | |||||||||||||||||||||||||||||
IBD | |||||||||||||||||||||||||||||
Sarcoidosis | |||||||||||||||||||||||||||||
Chronic hepatitis | |||||||||||||||||||||||||||||
Sweet syndrome | |||||||||||||||||||||||||||||
Acute Gout | |||||||||||||||||||||||||||||
Infections | Acute bacterial | toxic granulations, Döhle bodies, and cytoplasmic vacuoles in neutrophils | |||||||||||||||||||||||||||
Chronic | |||||||||||||||||||||||||||||
Viral infection | Children | ||||||||||||||||||||||||||||
granulomatous infections | |||||||||||||||||||||||||||||
bronchiectasis | |||||||||||||||||||||||||||||
Metabolic | Diabetic coma | ||||||||||||||||||||||||||||
Acidosis | |||||||||||||||||||||||||||||
Thyroid strom | |||||||||||||||||||||||||||||
Hypercortisolism | |||||||||||||||||||||||||||||
Seizures | |||||||||||||||||||||||||||||
Category | Condition | Etiology | Physiologic | Congenital | Acquried | Demography | History | Appearance | Fever | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | ESR/CRP | Gold standard | Associated findings | |||||||
Medications | Steriod | Release of granulocytes from the bone marrow | |||||||||||||||||||||||||||
myeloid growth factors | |||||||||||||||||||||||||||||
Lithium | |||||||||||||||||||||||||||||
Beta agonists | |||||||||||||||||||||||||||||
Cytokines | |||||||||||||||||||||||||||||
Catecholamines (epinephrine) | Stimulation of bone marrow myelopoiesis and/or egress into the circulation | ||||||||||||||||||||||||||||
ATRA | |||||||||||||||||||||||||||||
Allergy | |||||||||||||||||||||||||||||
Other | Post splenectomy | ||||||||||||||||||||||||||||
Down syndrome | |||||||||||||||||||||||||||||
Cigarette smoking | |||||||||||||||||||||||||||||
Stress/Exercise | |||||||||||||||||||||||||||||
Birth | |||||||||||||||||||||||||||||
Pregnancy | |||||||||||||||||||||||||||||
Platelet clumping | Spurious | ||||||||||||||||||||||||||||
Mixed cryoglobulinemia | Spurious | ||||||||||||||||||||||||||||
Category | Condition | Etiology | Physiologic | Congenital | Acquried | Demography | History | Appearance | Fever | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | ESR/CRP | Gold standard | Associated findings |